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Purpose: To report a novel de novo PAX6 mutation in an Ashkenazi-Jewish family with autosomal dominant aniridia.
Methods: A mother and her daughter of Ashkenazi-Jewish origin were diagnosed with aniridia. Blood samples were
drawn from family members and DNA was analyzed by direct sequencing and microsatellite marker analysis.
Results: The index patient and her daughter were affected with aniridia accompanied with congenital cataract, nystagmus,
and glaucoma. A heterozygous PAX6 frameshift mutation in exon 6 (c.577_578insG, insG@Gly72) was identified in the
affected  individuals  and  not  in  any  of  the  unaffected  family  members  including  the  parents  of  the  index  patient.
Microsatellite analysis revealed that the index patient inherited the disease haplotype from her unaffected father. A
sequence analysis of human PAX6 expressed sequence tags revealed the identification of spliced transcripts initiating from
introns 4, 6, 7, 8, and 11.
Conclusions: A novel de novo frameshift mutation in PAX6, which presumably occurred in the paternal gamete, was
found in a family with autosomal dominant aniridia. The location of the mutation suggests that only full-length PAX6
isoforms would be disrupted, indicating that the normal expression of shorter, paired-less, protein isoforms cannot prevent
manifestation of the disease.
Aniridia (OMIM 106210) is an inherited developmental
panocular disorder characterized by iris hypoplasia and is
usually accompanied by glaucoma, cataract, corneal opacity,
and foveal hypoplasia. The disease is mostly inherited in an
autosomal dominant mode with variable expressivity, and
about one-third of the patients are sporadic.
Autosomal  dominant  aniridia  is  caused  by  various
heterozygous mutations in the paired box gene-6 (PAX6) [1,
2], which encodes a transcription factor playing a major role
in developmental processes in several organs including the
eye [3,4]. Classic experiments have shown that knocking-out
PAX6 from the drosophila or mouse genome results in the
absence of the eye [5,6]. Heterozygous PAX6 mutations in
humans can also lead to a variety of ocular abnormalities such
as congenital cataract [7] and Peter's anomaly [8]. A recent
genotype-phenotype correlation analysis of 286 pathogenic
PAX6  mutations  revealed  that  mutations  that  introduce  a
premature termination codon into the open reading frame are
predominantly associated with aniridia [9].
A relatively large number of PAX6 mRNA sequences and
protein isoforms produced by alternative transcripts have been
reported in different species [10-15]. Some of these are named
paired-less since the encoded protein isoform does not contain
the paired domain which is very important for the function of
the PAX6 protein.
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We present here a de novo and novel PAX6 frameshift
mutation that causes aniridia in an Ashkenazi-Jewish family.
In addition, we performed sequence analysis of the human
PAX6  expressed  sequence  tags  (ESTs)  and  identified
transcripts  that  are  likely  to  encode  paired-less  protein
isoforms. We suggest that the normal expression of the paired-
less isoforms does not prevent the expression of the aniridia
phenotype.
METHODS
Two members of an Ashkenazi-Jewish family with aniridia
were  identified.  Over  the  years,  repeated  ophthalmologic
examinations were performed including best corrected visual
acuity, refraction, intraocular pressure, slit lamp examination,
and  funduscopy.  Both  affected  patients  also  underwent
surgical  procedures  as  detailed  below.  The  tenets  of  the
Declaration of Helsinki were followed, and informed consent
was obtained from all patients who participated in this study
before any donation of a blood sample. Blood samples were
obtained from the index patient, her affected daughter, and
unaffected family members for DNA analysis. Genomic DNA
was extracted from peripheral blood of all family members
using the FlexiGene DNA kit (Qiagen, Hilden, Germany).
Microsatellite  analysis  using  two  markers  (D11S904  and
D11S935)  flanking  PAX6  was  performed  using  the  ABI
PRISM 3700 system (Applied Biosystems, Foster City, CA).
Mutation  analysis  of  PAX6  was  performed  by  direct
sequencing of polymerase chain reaction (PCR) products.
The  PAX6  mutation  identified  in  this  study  has  been
deposited  in  the  Human  PAX6  Allelic  Variant  database
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142(accession  number  0000000367)  [16].  To  identify  PAX6
GenBank  entries  that  contain  intronic  sequences,  we
performed a BLAST analysis of each PAX6 intron against all
available  human  ESTs.  Splice-site  sequence  analysis  was
performed using the Splice Site Prediction by Neural Network
with a cutoff parameter of 0.1.
RESULTS
Clinical  description:  A  family  from  an  Ashkenazi-Jewish
ancestry (Figure 1A) was recruited for this study. The index
case (II-3) had no family history of visual impairment and
manifested total absence of the iris in the right eye, along with
a large iris coloboma in the left eye. She was also diagnosed
with  congenital  cataract,  nystagmus,  glaucoma,  corneal
dystrophy,  and  spherophakia.  Her  refractive  error  was
−4.5/-2.0x10° (right) and −2.0/-1.25x180° (left). Her visual
acuity (VA) was 6/60 at age 9 and 11 and dropped to counting
fingers (FC) at 30 cm at age 49. On examination at age 49,
intraocular pressure was 27 mmHg in the right eye (RE) and
25 mmHg in the left eye (LE). She was not receiving treatment
at this time. Corneas were vascularized in both eyes (BE).
Anterior chambers were deep, total aniridia was evident in the
RE, large iris coloboma was evident in LE, and remnants of
lens in BE (patient did not undergo previous cataract surgery).
Fundus details were difficult to see, but retinas were flat per
ultrasound. Her daughter (III-2) was diagnosed at the age of
two  months  with  aniridia,  congenital  cataract,  nystagmus,
glaucoma, and lack of a macular reflex. She underwent a
filtration procedure at the age of three months and was treated
with  various  topical  anti-glaucoma  medications  over  the
years. Refraction at five years of age was −1.5/-0.75x180°
(right) and −1.5/-0.50x180° (left). Her VA was 5/60 (RE) and
5/36 (LE) at the age of 14 years. At the age of 24 years she
underwent cataract surgery in both eyes, and at the age of 26
the intraocular lens (IOL) in the RE was repositioned. Her VA
dropped to FC 1 m (RE) and FC 2 m (LE) by the age of 30.
At that time, intraocular pressure was 31 mmHg in the RE and
21 mmHg LE. There was nystagmus and in both eyes the
corneas  were  vascularized,  with  poor  epithelialization.
Aniridia  was  noted  in  both  eyes  with  some  peripheral
remnants of iris adherent to the lens capsules. IOLs were
positioned in the sulcus in both eyes. Fundus details were
difficult to see, but significant cupping of both optic discs
(0.7–0.8) was noted. Treatment with Travoprost was initiated
in an attempt to lower intra-ocular pressure.
Molecular analysis: Mutation analysis of PAX6 in the index
patient revealed a heterozygous novel frameshift insertion (c.
577_578insG) within the paired domain in exon 6 (Figure 1B).
Her affected daughter was also found to be heterozygous for
this  mutation.  However,  none  of  her  unaffected  parents
carried this mutation. Aiming to study the inheritance of the
haplotype  carrying  the  mutation,  we  genotyped  two
microsatellite  markers  (D11S904  and  D11S935)  flanking
PAX6 in available family members (Figure 1A). Both affected
individuals  (II-3  and  III-2)  shared  the  disease-related
haplotype (213–202) while none of the unaffected siblings of
III-2 inherited this haplotype. The index patient inherited the
disease-related haplotype from her unaffected father who did
not carry the causative mutation. Aiming to verify paternity,
we genotyped four additional microsatellite markers located
on different autosomes (data not shown) and verified that
individual I-2 is indeed the biological father of II-3.
Figure 1. A novel de novo PAX6 mutation in an Ashkenazi-Jewish
family. A: A schematic representation of family MOL0407 is shown.
The black filled shapes denote individuals affected with aniridia. The
numbers above the symbols indicate the recruited individuals, and
the numbers within the symbols indicate the number of siblings. The
arrow indicates the index patient. The haplotype of each individual
is represented below the individual symbol. Numbers represent the
size of the PCR product containing the microsatellite sequence, "M"
represents the mutant allele, and "+" represents the normal allele.
B:  Sequence  analysis  of  exon  6  in  PAX6  is  shown.  The  upper
chromatogram represents the wild-type sequence of an unaffected
family  member,  and  the  lower  chromatogram  represents  a
heterozygous mutation (patient II-3). The position of the insertion is
indicated by an arrow. The wild type PAX6 amino acid sequence is
shown above the upper chromatogram and the mutant amino acid
sequence is shown below the lower chromatogram.
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To determine whether paired-less transcripts are produced by
the human PAX6, we performed a detailed analysis of PAX6
ESTs deposited in GenBank. We used BLAST analysis to
identify  PAX6  ESTs  that  contain  intronic  sequences  and
studied  the  composition  of  each  of  these  sequences.  We
identified  28  non-characterized  ESTs  with  full  or  partial
sequences of introns 4, 6, 7, 8, 9, 10, 11, and 12. A detailed
analysis  of  these  sequences  revealed  20  ESTs  with  no
evidence  for  splicing  events  (data  not  shown).  These
sequences were excluded from subsequent analyses since they
are likely to represent genomic contamination and not true
mRNA sequences. The remaining eight ESTs can be divided
by the intron from which the putative alternative transcription
starts:  two  ESTs  from  the  evolutionary-conserved  alpha
promoter/enhancer within intron 4 [17], two from intron 6,
one from intron 7, one from intron 8, and two from intron 11
(Figure 2). An analysis of splicing events in these sequences
revealed four sites in which alternative splicing occurred in
the  human  PAX6,  some  of  which  have  been  previously
described in mammalian and non-mammalian species. The
two ESTs initiating from the alpha promoter/enhancer share
the same splicing event (a splice site score of 0.17). One of
the intron 6 ESTs (BQ776835) contains a strong novel splice
site (score of 0.85) while the second EST (CD675778) shows
no splicing event within intron 6. A fourth novel splicing event
was identified within intron 7 (score of 0.30). The remaining
ESTs do not show intronic splicing events but do contain
splicing at the canonical PAX6 splice sites and are therefore
regarded as true mRNA transcripts. All eight EST sequences
initiating from intronic regions are expected to encode short
paired-less  PAX6  isoforms  with  an  open  reading  frame
starting within exon 7, exon 8, exon 11, or intron 11 (Figure
2)
Figure  2.  A  schematic  representation  of  the  human  PAX6  and
expressed sequence tags (ESTs) initiating from intronic regions.
The upper panel illustrates the structure of the human PAX6. Only the
genomic  region  containing  the  coding  exons  is depicted with
arrows indicating the location of the initiation codons. The regions
covered  by  each  of  the  eight  spliced  ESTs  containing  intronic
sequences are depicted below. Spliced out regions are illustrated as
a thin line.
DISCUSSION
The identified novel mutation in PAX6, which occurred de
novo in our index patient, is likely to result in a transcript that
is recognized by the nonsense-mediated mRNA decay (NMD)
system [18] and therefore will be degraded, resulting in a 50%
reduction of the full-length PAX6 protein. This result is in-
line  with  the  suggested  genotype-phenotype  correlation
analysis of PAX6 [9], showing that frameshift and nonsense
mutations usually result in the aniridia phenotype.
A large proportion of genes in the human genome encode
more than one protein isoform through alternative splicing or
alternative initiation of transcription. PAX6 might be one of
the extreme cases in which multiple alternative promoters and
multiple alternative splice-sites generate a large number of
protein  isoforms  [14,15,19].  One  of  the  most  intriguing
questions regarding PAX6 is: What is the function, if there is
one, of the short, paired-less, isoforms? The existence of short
mRNA transcripts transcribed from PAX6 has been described
in a variety of species including those initiating from introns
4, 6, 7, and 11 [14,15,20]. Some of these transcripts have been
shown to be translated to paired-less PAX6 isoforms and in
some cases, have a unique expression pattern, which is highly
conserved along evolution [19]. Overexpression of a paired-
less isoform in the mouse retina revealed a microphthalmic
phenotype [15]. These observations suggest that the paired-
less isoforms have a function that is different from the current
function  attributed  to  the  PAX6  protein.  However,  the
existence of such transcripts was not studied in humans. Our
analysis  of  all  PAX6  ESTs  as  presented  here  shows  that
alternative promoters are likely to be active in the human
PAX6 within introns 4, 6, 7, and 11 as previously described in
other  species  [14,15,19].  In  addition,  one  EST  sequence
indicates that another alternative promoter might be located
within intron 8. The predicted amino acid sequence of these
transcripts revealed that all ESTs initiated within introns 4 and
6 result in the same protein isoform while shorter isoforms
might be produced by the transcripts initiating from introns 8
and 11. Nonetheless, all of these isoforms do not contain the
paired region in their open reading frame.
The c.577_578insG mutation identified here (as well as
other null mutations previously reported in exon 6) are not
expected to disrupt these shorter isoforms since exon 6 is not
part  of  their  open  reading  frame  [14,15,20].  Thus,  these
isoforms are probably expressed from the mutant allele even
without the expression of the full-length protein. Our results
indicate that the mechanism by which null PAX6 mutations
cause aniridia might be either haploinsufficiency of the full-
length PAX6 protein or an aberrant ratio of full-length to
paired-less protein isoforms.
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